Search

Displaying results 1111 - 1120 of 10000 in total
  1. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].

    Synonyms: 4'-N-benzoylstaurosporine
  2. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism. … [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]

    Mixtures: Primaxin Im, Primaxin IV
  3. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]

  4. Drug

    Ciclopirox

    go.drugbank.com/drugs/DB01188
    ApprovedInvestigational

    In particular, the agent is especially effective in treating Tinea versicolor. … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.

  5. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    , and improvements in CF symptoms. … results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes.

  6. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.

  7. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … [A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [

  8. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

    Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors
  9. Indication

    Facial Skin Wrinkles

    go.drugbank.com/conditions/DBCOND0057699
    Drugs: Botulinum toxin type A
    Synonyms: Lined face
  10. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [L44918,L44948] It received a similar approval in the EU in September 2023. … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.